142 related articles for article (PubMed ID: 38148718)
21. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
Shen Y; Wang S; Wu Y
Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
24. Identification of a methyltransferase-related long noncoding RNA signature as a novel prognosis biomarker for lung adenocarcinoma.
Sun YY; Li S; Liu C; Pan Y; Xiao Y
Aging (Albany NY); 2024 May; 16(10):8747-8771. PubMed ID: 38771129
[TBL] [Abstract][Full Text] [Related]
25. Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma.
Wang N; Xu Y; Jin L; Wang X; Wu S; Wang Y; Zhao J; Zhou F; Ge H
Dis Markers; 2022; 2022():1829528. PubMed ID: 36051357
[TBL] [Abstract][Full Text] [Related]
26. Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs.
Zheng M; Zhou H; Xie J; Zhang H; Shen X; Zhu D
J Thorac Dis; 2022 Dec; 14(12):4828-4845. PubMed ID: 36647499
[TBL] [Abstract][Full Text] [Related]
27. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
28. Identification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma.
Zhang Y; Jia Q; Li F; Luo X; Wang Z; Wang X; Wang Y; Zhang Y; Li M; Bian L
Sci Rep; 2024 Mar; 14(1):7543. PubMed ID: 38555384
[TBL] [Abstract][Full Text] [Related]
29. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System.
Gao C; Li H; Ma W; Zhang Q; Liu C; Liu L; Zhuang J; Sun C
J Immunol Res; 2022; 2022():7519838. PubMed ID: 36061307
[TBL] [Abstract][Full Text] [Related]
31. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
32. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
Huang X; Wang HF; Huang S
Front Genet; 2022; 13():906880. PubMed ID: 36061188
[No Abstract] [Full Text] [Related]
33. Methylation of N6 adenosine-related long noncoding RNA: effects on prognosis and treatment in 'driver-gene-negative' lung adenocarcinoma.
Yang HS; Cai HY; Shan SC; Chen TF; Zou JY; Abudurufu M; Luo HH; Lei YY; Ke ZF; Zhu Y
Mol Oncol; 2023 Feb; 17(2):365-377. PubMed ID: 36221911
[TBL] [Abstract][Full Text] [Related]
34. An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.
Zhang H; Hu J; Liu A; Qu H; Jiang F; Wang C; Mo S; Sun P
Front Cell Dev Biol; 2021; 9():651575. PubMed ID: 34307344
[TBL] [Abstract][Full Text] [Related]
35. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
36. A novel algorithm for lung adenocarcinoma based on N6 methyladenosine-related immune long noncoding RNAs as a reliable biomarker for predicting survival outcomes and selecting sensitive anti-tumor therapies.
Yan Q; Hu B; Chen H; Zhu L; Lyu Y; Qian D; Shao G
J Clin Lab Anal; 2022 Sep; 36(9):e24636. PubMed ID: 35949000
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Ma Y; Yang J; Ji T; Wen F
Front Genet; 2022; 13():990623. PubMed ID: 36246622
[TBL] [Abstract][Full Text] [Related]
38. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
39. Identification of m6A-related lncRNAs-based signature for predicting the prognosis of patients with skin cutaneous melanoma.
Lin W; Tan ZY; Fang XC
SLAS Technol; 2024 Feb; 29(1):100101. PubMed ID: 37541541
[TBL] [Abstract][Full Text] [Related]
40. A ferroptosis-related LncRNAs signature for predicting prognoses and screening potential therapeutic drugs in patients with lung adenocarcinoma: A retrospective study.
Dong J; Tao T; Yu J; Shan H; Liu Z; Zheng G; Li Z; Situ W; Zhu X; Li Z
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1925. PubMed ID: 38043920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
